Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1996 2
1997 1
1998 1
1999 6
2000 3
2001 3
2002 1
2003 5
2004 8
2005 7
2006 13
2007 9
2008 9
2009 9
2010 11
2011 13
2012 16
2013 7
2014 11
2015 16
2016 15
2017 16
2018 26
2019 28
2020 27
2021 33
2022 31
2023 36
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S. Peyrin-Biroulet L, et al. Among authors: sands be. J Crohns Colitis. 2024 Apr 13:jjae038. doi: 10.1093/ecco-jcc/jjae038. Online ahead of print. J Crohns Colitis. 2024. PMID: 38613425
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.
Pai RK, D'Haens G, Kobayashi T, Sands BE, Travis S, Jairath V, De Hertogh G, Park B, McGinnis K, Redondo I, Lipitz NG, Gibble TH, Magro F. Pai RK, et al. Among authors: sands be. Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21. Expert Rev Gastroenterol Hepatol. 2024. PMID: 38509826 Review.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A. Sands BE, et al. Inflamm Bowel Dis. 2024 Mar 9:izae024. doi: 10.1093/ibd/izae024. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38459910
334 results